key: cord-0896593-4ngqg055
authors: Benlarbi, Mehdi; Laroche, Geneviève; Fink, Corby; Fu, Kathy; Mulloy, Rory P.; Phan, Alexandra; Ariana, Ardeshir; Stewart, Corina M.; Prévost, Jérémie; Beaudoin-Bussières, Guillaume; Daniel, Redaet; Bo, Yuxia; Yockell-Lelièvre, Julien; Stanford, William L.; Giguère, Patrick M.; Mubareka, Samira; Finzi, Andrés; Dekaban, Gregory A.; Dikeakos, Jimmy D.; Côté, Marceline
title: Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron
date: 2022-02-22
journal: bioRxiv
DOI: 10.1101/2022.02.19.481107
sha: 9facd32f12e701bf982777f82109d206728e032d
doc_id: 896593
cord_uid: 4ngqg055

To infect cells, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) via its spike glycoprotein (S), delivering its genome upon S-mediated membrane fusion. SARS-CoV-2 uses two distinct entry pathways: 1) a surface, serine protease-dependent or 2) an endosomal, cysteine protease-dependent pathway. In investigating serine protease-independent cell-cell fusion, we found that the matrix metalloproteinases (MMPs), MMP2/9, can activate SARS-CoV-2 S fusion activity, but not that of SARS-CoV-1. Importantly, metalloproteinase activation of SARS-CoV-2 S represents a third entry pathway in cells expressing high MMP levels. This route of entry required cleavage at the S1/S2 junction in viral producer cells and differential processing of variants of concern S dictated its usage. In addition, metalloproteinase inhibitors reduced replicative Alpha infection and abrogated syncytia formation. Finally, we found that the Omicron S exhibit reduced metalloproteinase-dependent fusion and viral entry. Taken together, we identified a MMP2/9-dependent mode of activation of SARS-CoV-2 S. As MMP2/9 are released during inflammation and severe COVID-19, they may play important roles in SARS-CoV-2 S-mediated cytopathic effects, tropism, and disease outcome.

significative effect for one of the MMP9-specific dsiRNA (#1), although significant reduction was seen 241 when in combination with a MMP2-specific dsiRNA (#2). In contrast, there was no difference in syncytia 242 formation for cells transfected with the scramble dsiRNA ( Fig.4 .AB). These results strongly suggest that 243 MMP2 and MMP9 are playing critical roles in the metalloproteinase-dependent SARS-CoV-2 S-mediated 244 fusion. 245

We next sought to validate our findings with replicative SARS-CoV-2. Alpha was used to infect 248 HT1080-ACE2 cells overnight in the presence of camostat, E64d, TAPI-2, GIX, or vehicle. The next day, cells 249 were fixed and stained for S protein (S) and nucleocapsid protein (N) to visualize infected cells and an 250 ELISA on N was performed in parallel to quantify infection. We found that Alpha infection of the HT1080-251 ACE2 cells led to the formation of large multinucleated cells in vehicle, camostat and E64d-treated cells 252 (Fig.5A, S3 ). While E64d treatment did not prevent syncytia formation, fewer infected cells were observed 253 and N levels were significantly decreased (Fig.5AB, S3 ). This suggested that cathepsin inhibition decreases 254 infection and viral replication, but not S-mediated cell-cell fusion of infected cells. Similarly, 255 metalloproteinase inhibitors also decreased both the number of infected cells and N expression levels 256 measured by ELISA. However, these drugs also completely blocked syncytia formation (Fig.5AB, S3) , 257

indicating that metalloproteinases facilitate both entry and cell-cell fusion. Therefore, in agreement with 258 the VLP assays, in HT1080-ACE2 cells, a proportion of Alpha infections proceeded in a cathepsin-259 dependent manner, while other infections proceeded in a metalloproteinase-dependent manner. This 260 alternative usage of cathepsin or metalloproteinases is likely linked to the processing efficiency of the 261 incorporated S glycoprotein. 262

Since its emergence and discovery, Omicron has spread rapidly worldwide and became the dominant 265 circulating SARS-CoV-2 variant [49] . Interestingly, recent studies have reported decreased processing of 266 the spike glycoprotein and potential reduced activation by TMPRSS2 [11, 50] . Given that our findings 267 support a model by which metalloproteinase usage is dictated by S cleavage at the S1/S2 junction, we 268 sought to investigate whether the Omicron S could be activated in a metalloproteinase-dependent 269 manner. We first performed cell-cell fusion assays using 293T-ACE2 cells as effector cells in the presence 270 or absence of TMPRSS2 expression (Fig.6A ). Interestingly, we found that Omicron S mediated only modest 271 fusion in the absence of TMPRSS2, in contrast to the ancestral, D614G, Alpha, or Delta variant S. As 272 expected, Omicron S fusion activity was enhanced in the presence of TMPRSS2, albeit to a slightly lower 273 extent compared to the other SARS-CoV-2 S tested (Fig.6A ). In addition, as previously reported and in 274 accordance with our model, the ratio of S2/S0 in cell lysates was reduced for Omicron when compared to 275 D614G (Fig.6B) . 276 We next assessed the preferential entry route employed by Omicron S using VLPs. We found that, similarly 277 to other SARS-CoV-2 variants, Omicron used the endosomal cathepsin-dependent pathway in 293T-ACE2 278 cells and the surface, serine protease-dependent pathway in Calu-3 cells (Fig.6C ). However, strikingly, 279

Omicron did not use the metalloproteinase-dependent pathway in HT1080-ACE2 cells and strictly used 280 the endosomal route (Fig.6C) . Further, compared to Alpha, D614G and Delta VLP, Omicron used the 281 TMPRSS2-dependent pathway in Calu-3 cells less efficiently, but had similar entry efficiency to D614G in 282 293T-ACE2 and HT1080-ACE2 cells (Fig.S4 ). Taken together, our data suggest a shift in protease usage by 283

Omicron, which may play a part in the differential tropism and pathogenicity observed for this variant. 284

Previous studies have shown that SARS-CoV-1 and SARS-CoV-2 can enter cells via two distinct 286 ACE2-dependent pathways: a serine protease and a cysteine protease pathway [5, 6] . Here we show that 287 the SARS-CoV-2 wild-type and variant of concerns (VOCs) S glycoprotein can be triggered via a third 288 mechanism that is dependent on secreted metalloproteinases (MMPs), specifically MMP2 and MMP9, for 289 cell-cell fusion and viral entry. The ability to use this entry pathway required high expression of these 290 proteases and proteolytic processing at the S1/S2 boundary in viral producer cells. Accordingly, usage of 291 this pathway by SARS-CoV-2 variants correlated with differential extents of S processing in viral producer 292 cells; the S of Delta preferentially entered via the metalloproteinase route when available, while the S of 293

Omicron did not. Given that metalloproteinases such as MMP2/9 are released and highly expressed in the 294 context of lung damage and inflammation during severe COVID-19, this mechanism of activation could 295 play critical roles in S-mediated cytopathic effects, tropism, and overall pathogenesis. 296

With previous work reporting the presence of syncytia in the lung of deceased COVID-19 patients 297 [42, 51] , the ability of SARS-CoV-2 S to mediate cell-to-cell fusion has been hypothesized to play roles in 298 both pathogenesis and virus cell-to-cell propagation [51] [52] [53] . The formation of such multinucleated cells 299 is believed to occur by the activation of SARS-CoV-2 S expressed at the cell surface of infected cells [54] 300 and fusion with neighboring cells expressing ACE2 and serine proteases. However, the relative low 301 abundance of ACE2+ and TMPRSS2+ cells in the lower airways suggests that there may be additional 302 factors able to activate S [55] [56] [57] [58] . Serine protease-independent SARS-CoV-2 S-mediated cell-cell fusion has 303 been previously observed in vitro and reported by other studies [16, 17] . Here we show that 304 metalloproteinases, including MMP2 and MMP9, are critical factors in SARS-CoV-2 S serine protease-305 independent fusion (Fig.1E,4 ,5). More precisely, knockdown of MMP2 and MMP9 reduced S-mediated 306 syncytia formation in the absence of serine proteases (Fig.4 ). In addition, Alpha infection and replication 307 in cells expressing high levels of MMP2 and MMP9 led to substantial fusion of infected cells that was 308 abrogated by broad-spectrum MMP inhibitors (Fig.5) . Several studies have demonstrated increased levels of MMP2 and MMP9 in patients with severe COVID-19, which associated with disease outcome [20, 22, 310 59, 60] . In addition, infiltrating and activated neutrophils, which are potent source of released 311 are both associated with severe [61] [62] [63] [64] . Our studies suggest a model by which inflammation 312 and MMP production during COVID-19 increase viral cell-to-cell transmission and exacerbate virus-313 induced cytopathic effects further contributing to disease. 314

We demonstrated that entry of SARS-CoV-2 lentiviral particles, virus-like particles and authentic 315

Alpha variant into host cells can occur in a metalloproteinase-dependent manner (Fig.2E,3E,5B ). This 316 previously unrecognized entry pathway depended on S1/S2 processing in the viral producer cells (Fig.2,3 , 317 6). Therefore, this third entry route is specific to SARS-CoV-2 and cannot be used by SARS-CoV-1, as SARS-318

CoV-1 S does not contain the critical S1/S2 furin cleavage site. Whether this additional entry pathway 319 unique to SARS-CoV-2 played a role in its high transmissibility remain to be determined. Multiple variants 320 of SARS-CoV-2 have emerged since the beginning of the COVID-19 pandemic, with each having their own 321 sets of mutations that enhance immune escape and transmissibility. Interestingly, variants such as Alpha, 322 Delta, Kappa and more recently Omicron possess mutations within the S1/S2 furin cleavage site. Notably, 323 Delta S harbors the P681R mutation which improves S1/S2 processing and fitness over that of the 324 ancestral virus and Alpha, which possesses the P681H mutation [12, [65] [66] [67] . Other studies, including ours, 325 have shown that Omicron S is less efficiently processed at the S1/S2 junction compared to ancestral S, S 326 with a D614G mutation (Fig.6B) , and those of VOCs such as Delta [68, 69] . Therefore, as expected, we 327 found that Omicron S mediated reduced metalloproteinase-dependent cell-cell fusion (Fig.6A) . In 328 addition, VLPs expressing Omicron S were only slightly sensitive to metalloproteinase-dependent entry. 329 Omicron S has two mutations near the furin cleavage site, N679K and P681H, however the mechanism by 330 which these or other mutations alter S processing remains to be determined. In addition, whether the 331 inefficient use of the metalloproteinase pathway for activation of S to mediate viral entry and cell-cell 332 fusion plays a role in the apparent distinct clinical manifestations and tropism of Omicron is unclear [11, [70] [71] [72] [73] . Nonetheless, our findings of an additional entry pathway suggest a potential for increased tropism 334 in the presence of MMPs during inflammation to cells that do not express serine proteases and could play 335 important roles in dissemination and disease severity. 336

While this manuscript was in preparation, Yamamoto et al. reported in a pre-print a SARS-CoV-2 337 S-mediated metalloproteinase-dependent entry pathway in which ADAM10 was partially involved in 338 different cell lines [74] . Although we have not directly studied a role for ADAM10 and it is still unknown if 339 ADAM10 can cleave SARS-CoV-2 S, our findings and those of Yamamoto and colleagues highlight the 340 promiscuity of SARS-CoV-2 for host protease activation of S and intensifies the hurdles in the usage of 341 host protease inhibitors for therapeutic purposes. Interestingly, unlike S activation mediated via 342 cathepsins or serine proteases, the S activation triggered via metalloproteinases required prior S 343 processing at the S1/S2 junction. While more work is needed to determine whether MMP2, MMP9, and 344 other metalloproteinases directly cleave S, the requirement for a processed S suggest that 345 metalloproteinases can only cleave at the S2' site. Further studies are required to characterize the specific 346 roles played by the metalloproteinases and to determine the specific S cleavage site involved in the 347 metalloproteinase pathway. 348

Previous studies investigating immune signatures of severe COVID-19 unveiled vascular 349 endothelial growth factor A (VEGF-A), a disintegrin and metalloproteinases (ADAMs) and matrix 350 metalloproteinases (MMPs) as potential markers for severe disease progression [21, 75, 76] . Our data 351 indicate that increased secretion of MMPs during severe COVID-19 could exacerbate S-mediated 352 cytopathic effects such as syncytia formation. Furthermore, it could also expand tropism by allowing entry 353 in serine protease deficient cells, and potentially even in ACE2 deficient cells promoted by shed ACE2 354 induced by ADAM17 activity [77] . Therefore, usage of the metalloproteinase pathway by current and 355 future circulating SARS-CoV-2 variants could have profound implications in disease severity, outcome, and 356 potential sequelae following recovery. 357

HEK293T (ATCC), HEK293T-ACE2 (kind gift of Hyeryun Choe, Scripps Research), HT1080 cells (ATCC) and 360

Calu3 (ATCC) were cultured in Dulbecco's Minimum Essential Medium (DMEM) supplemented with 10% 361 fetal bovine serum (FBS, Sigma), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.3 mg/mL L-362 glutamine. HT1080 cells stably expressing ACE2 were generated by infection with lentiviral particles 363 generated with psPAX2, pMDG and pLENTI_hACE2_PURO (gift from Raffaele De Francesco (Addgene 364 plasmid # 155295)) and selection of a polyclonal HT1080-ACE2 cells using 2 µg/mL puromycin. Cells were 365 maintained at 37°C, 5% CO2 and 100% relative humidity. 366

The inhibitors Camostat mesylate, GI-254023X and Batimastat were purchased from Cayman Chemical. 367

E64d and MMP-2/MMP-9 Inhibitor II were from MilliporeSigma and TAPI-2 from Tocris. 368

The monoclonal antibodies SARS-CoV-1/SARS-CoV-2 Spike Protein S2 (1A9) and SARS-CoV-1/SARS-CoV-2 369 Nucleocapsid (6H3) were purchased from ThermoFisher Scientific. The rabbit polyclonal Anti-GAPDH 370 antibody were purchased from Abcam. The rabbit polyclonal Anti-HIV-1 p24 antibody was purchased from 371

MilliporeSigma. The mouse anti-N protein antibody (clone 1C7) was purchased from Bioss Antibodies, and 372 the rabbit anti-SARS-CoV-2 spike protein (clone 007) antibody, was purchased from Sino Biological. 373

The Spike gene sequence from the severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 375 (NC_045512.2) was codon optimized (GeneArt, ThermoFisher) and gene blocks with overlapping 376 sequences were synthesized by Bio Basic Inc (Markham, Ontario, Canada). The full gene, untagged or with 377 a N-terminal FLAG tag, was reconstituted by Gibson assembly, amplified by PCR, and cloned in pCAGGS. 378

Untagged S mutants (D614G, R815A, and Δ Furin site (deletion of arginine 682, 683 and 685), Δ675-679, and variants (Alpha, Delta, Omicron) were generated by overlapping PCR and described elsewhere [78-380 81] . 381

FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density of 1 x 10 6 383 cells/mL at 37°C with 8 % CO2 with regular agitation (150 rpm). Cells were transfected with a plasmid 384 coding for His(8)Tagged-ACE2 ectodomain (residues 1-615; [82]) using ExpiFectamine 293 transfection 385 reagent, as directed by the manufacturer (Invitrogen). One week later, cells were pelleted and discarded. 386

Supernatants were filtered using a 0.22 µm filter (Thermo Fisher Scientific). The soluble ACE2 (sACE2) was 387 purified by nickel affinity columns, as directed by the manufacturer (Invitrogen). The sACE2 preparations 388 were dialyzed against phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To 389 assess purity, recombinant proteins were resolved by SDS-PAGE and stained with Coomassie Blue. 390

For the syncytium formation assay HEK293T and HEK293T-Ace2 cells were seeded in 24-well plates and 392 grown to approximately 80% confluency. Cells were then transiently transfected with plasmid DNA 393 encoding LTR-GFP (kind gift of James Cunningham, Brigham and Women's Hospital, Boston), FLAG-SARS-394 CoV2 S wt or indicated mutants, and TMPRSS2 or pCAGGS in a 1:2:5 ratio using jetPRIME (Polyplus-395 transfection). Simultaneously, cells were placed in fresh complete media (DMEM supplemented with 10% 396 FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-glutamine) with 25 µM of Camostat or 397 vehicle control DMSO. 24 hours post transfection, cells were imaged for syncytium formation using a ZOE 398 Fluorescent Cell Imager (Bio-Rad) and three different fields for each well were obtained. 399

Cell-cell fusion assay with soluble ACE2, effector HEK293T cells were transiently transfected with plasmid 400 DNA encoding mCherry, and SARS-CoV2 spike and target HEK293T cells were transiently transfected with 401 plasmid DNA encoding LTR-GFP, TMPRSS2 or pCAGGS. 24 h post-transfection, effector and target cells were resuspended with 0.56 mM EDTA in PBS and co-cultured in complete media at a 1:1 ratio in the 403 presence of increasing concentrations of soluble ACE2 (0, 25, 50, 100, 150 µg/mL). Cells were imaged 10h 404 post-co-culture using a ZOE Fluorescent Cell Imager (Bio-Rad). 405

For the ZipVenus complementation cell fusion assay, HEK293T cells were seeded in a 12-well microplate 406 (500,000 cells/well) in complete media for 24h. Transient transfections were performed using JetPRIME 407 (Polyplus transfection, France) according to the manufacturer's instructions. Target cells were transfected 408 with ZipV1 (0.5µg) alone or with hACE2/pcDNA3 (0.05µg) with or without TMPRSS2/plX307(0.45µg). 409

Effector cells population were transfected with ZipV2 (0.5µg) and SARS-CoV-2-S (0.125µg). Total DNA was 410 normalized using the empty pCAGGS vector DNA to 1µg. Following transfection, cells were incubated at 411 37 °C for 24 h. Then, cells were rinsed with PBS and detached with versene (PBS, 0.53mM EDTA) and 412

counted. 40,000 cells/well of both populations were co-seeded in complete DMEM without phenol red 413 in a 384-well black plate with optical clear bottom and incubated for 3 hours at 37 °C, 5% CO2. Bimolecular 414 fluorescence complementation (BiFC) signal was acquired using Biotek Synergy Neo2 plate reader (BioTek) 415 using monochromator set to excitation/emission of 500 and 542 nm. The original BiFC constructs GCN4 416 leucine zipper-Venus1 (ZipV1) and GCN4 leucine zipper-Venus2 (ZipV2) were sourced from Stephen W. 417 Michnick [83] . 418

Total RNA was extracted using RNeasy Mini Kit (Qiagen, 74104) according to manufacturer's instructions. 420 RNA concentrations were determined using Thermo Scientific™ NanoDrop 2000. Complementary DNA 421 was synthesized using iScript™ Reverse Transcription Supermix (Bio-Rad, 1708840) and qRT-PCR analysis 422 was performed using SYBR Green master mix (Life Technologies) on a Bio-Rad CFX96™ RT-PCR system. 423

HEK293T, HEK293T-ACE2, Calu3 and HT1080 cells were analyzed for MMP2 and MMP9 activity through 426 zymographic analysis. Cells were plated in a 6-well plate, at 70-80% confluency, media was changed for 427 FBS-free DMEM (conditioned media). Conditioned media were collected after 24h, centrifuged to remove 428 debris and concentrated 10X using Amicon Ultra-Centrifugal filter units with a 10kD cutoff 429 (MilliporeSigma). Total protein concentration was measured using BCA. 40µg of protein per sample were 430 diluted in a non-reducing sample buffer (4% SDS, 20% glycerol, 0.01% bromophenol blue, 125 mM Tris-431

HCl, pH6.8) and loaded to a 10% Zymogram Plus (Gelatin) protein gel from Invitrogen. Following 432 electrophoresis, gels were washed twice for 30 min in washing buffer (2.5% Triton X-100, 50mM Tris-HCl, 433 pH7.5, 5mM CaCl2 and 1µM ZnCl2) at room temperature with gentle agitation. Gels were next incubated 434 overnight at 37 degrees in development buffer (1%Triton X-100, 50mM Tris-HCl, pH7.5, 5mM CaCl2 and 435

1µM ZnCl2) to initiate enzymatic activity. Gels were stained with Coomassie Blue 0.5% for 1h and distained 436 with 10% acetic acid and 40% methanol before being scanned. 437

HEK293T cells were transiently co-transfected with lentiviral packaging plasmid psPAX2 (gift from Didier 439 Trono, addgene #12260), lentiviral vector encoding LacZ or luciferase, and a plasmid encoding the viral 440 glycoprotein (CoV S or VSV G) at a 1:1:1 ratio using jetPRIME transfection reagent. The supernatant was 441 harvested at 48, 72, and 96 h post-transfection and filtered with a 0.45 µM filter. Lentivirus particles were 442 concentrated via ultra-centrifugation (20,000 RPM, 1.5h, 4˚C) with a sucrose cushion (20% w/v). Viral 443 particles were resuspended with PBS and stored at -80˚ C. 444 Cells were seeded in 96-well plates to achieve approximately 50% confluence after 24 h. After 24 h, cells 445

were pre-incubated with the inhibitor(s) for 1 h diluted in the respective standard growth media with 5 446 µg/mL polybrene. Concentrated lentiviruses were also diluted in growth media containing polybrene to 447 achieve between 100-200 foci following infection. After 24 h incubation with virus and inhibitors, cells were placed in fresh growth media. 72 h post-infection, cells were fixed in formalin and stained with 100 449 µM X-Gal in staining solution (5 mM potassium ferrocyanide, 2 mM magnesium chloride in PBS) and 450

incubated at 37˚ C for 16-24 h. Positive foci were manually counted using a light microscope. Inhibitor 451 focus-forming units (FFUs) were normalized to vehicle control. 452 For VLP infection, cells were seeded in 96-well plates to achieve approximately 70% confluence the 463 following day. After 24 h, cells were pre-incubated with the inhibitor(s) for 1 h diluted in 2% serum growth 464 media with 5 µg/mL polybrene. Concentrated VLPs were also diluted in 2% serum growth media 465 containing polybrene. After 20-24 h incubation with VLP and inhibitors, supernatant was removed, and 466 cells were rinsed in 1X PBS and lysed by the addition of 40 µl passive lysis buffer (Promega) followed by 467 one freeze-thaw cycle. A Synergy Neo2 Multi-Mode plate reader (BioTek) was used to measure the 468 luciferase activity of each well after the addition of 50-100 µl of reconstituted luciferase assay buffer 469 (Promega). Inhibitors were normalized to vehicle control. 470

293T-ACE2 and HT1080-ACE2 cells were seeded in 24-well plates and 6-well plates respectively to achieve 472 70% confluency after 4-6 hours and then transfected with Lipofectamine RNAiMAX (Thermofisher) using 473 the indicated dsiRNAs (IDT , Table S1 ) at a final concentration of 10nM. Combination of dsiRNA was 474 performed using a 1:1 ratio to obtain a final concentration of 10nM. After 20 hours, 293T-ACE2 were used 475 to perform the syncytia assay as described above, and HT1080-ACE2 media was changed to conditioned 476 media for gelatin zymography as described above. Time-course imaging of the syncytia formation was 477 performed using an Incucyte-Zoom (EssenBioscience), and images were analyzed in imageJ to measure 478 the percentage of green surface area over background. 479

Cells were washed in PBS and then lysed in cold lysis buffer (1% Triton X-100, 0.1% IGEPAL CA-630, 150mM 481 NaCl, 50mM Tris-HCl, pH 7.5) containing protease and phosphatase inhibitors (Cell Signaling). Proteins in 482 cell lysates were resolved by SDS-PAGE and transferred to polyvinylidenedifluoride (PVDF) membranes. 483

Membranes were blocked for 1h at RT with blocking buffer (5% skim milk powder dissolved in 25mM Tris, 484 pH 7.5, 150mM NaCl, and 0.1% Tween-20 [TBST]). Blots were washed in TBST and proteins were detected 485 using the indicated primary antibodies, HRP-conjugated secondary antibodies, and visualized using 486 chemiluminescence according to manufacturer protocol (Bio-Rad Clarity ECL substrate). 487

A previously described in vitro microneutralization assay [85, 86] with 100 μL appropriate inhibitor dilution (or vehicle control). Promptly, 2x10 3 TCID50/mL SARS-CoV-2 502 alpha variant was prepared in a Biosafety Level 3 laboratory (ImPaKT Facility, Western University) and a 503 volume corresponding to 100 TCID50 virus per well was added to wells already containing inhibitor or 504 vehicle diluted in media. An equivalent volume of media void of virus was added to uninfected control 505 wells. All wells were gently mixed and cultured overnight at 37°C/5% CO2. 506

After overnight culture, media was discarded and replaced with 10% formaldehyde for >24 hours to cross-507 link cell monolayers. Wells were washed with PBS, permeabilized for 15 minutes with PBS + 0.1% Triton 508 X-100 (BDH Laboratory Reagents), washed again in PBS and then blocked for one hour with PBS + 3% non-509 fat milk. At this point, one plate was processed as detailed previously [85] to quantify virus infection. 510

Briefly, a mouse anti-SARS-CoV-2 nucleocapsid (N) protein primary antibody and an anti-mouse IgG HRP 511 secondary antibody in conjunction with SIGMAFAST™ OPD developing solution (Millipore Sigma) 512 permitted SARS-CoV-2 infection quantification. The optical density at 490 nm served as the assay readout 513 and was measured using a Synergy LX multi-mode reader and Gen5 microplate reader and imager 514 software (Agilent). 515

In parallel and after blocking, the second plate was incubated for one hour with a primary antibody 516 solution formulated in PBS + 1% non-fat milk containing both mouse anti-N protein (1 μg/mL, clone 1C7) 517 and rabbit anti-SARS-CoV-2 spike protein (1:500 dilution, clone 007) antibodies. Extensive washing with PBS ensued, followed by a 45-minute incubation with donkey anti-mouse IgG Alexa Fluor Plus 488 (1 519 μg/mL, Invitrogen), donkey anti-rabbit IgG Alexa Fluor Plus 594 (2 μg/mL, Invitrogen) antibodies and DAPI 520

(1:1000, Millipore Sigma) in PBS + 0.5% BSA consisting of. All wells were then washed three times in PBS, 521 monolayers were covered with minimal PBS and fluorescence images were acquired with an EVOS™ 522 M7000 Imaging System (Invitrogen). 523

Data are expressed as mean ± standard deviation of the mean (SD). Significance was determined by 525 analysis of variance (one-way ANOVA) followed by a Dunnett's multiple comparisons test. A p-value lower 526 than 0.05 was used to indicate a statistically significant difference ****, P <0.0001, ***, P <0.001,** , P 527 <0.01, , P *<0.05. Statistical analyses were performed with GraphPad Prism 9. 528

We would like to acknowledge technical support from the uOttawa Flow Cytometry & Virometry Core 530 Facility and the uOttawa Cell Biology and Image Acquisition Core Facility. We would also like to 531 acknowledge support from the Western University ImPaKT staff for maintaining the facility needed for 532 our work. 533 

The authors declare that no conflict of interest exists. 560

Schematics of the S glycoprotein and amino acid sequences at the S1/S2 and S2' cleavage sites of mutants 563 used in this study. In red, amino acids surrounding the cleavage sites, and arrow heads depict the cleavage 564 site. (Created with BioRender) (B, D) 293T or 293T stably expressing ACE2 were co-transfected with 565 plasmids encoding GFP, SARS-CoV-1 or SARS-CoV-2 S WT or indicated mutants, and TMPRSS2, or with an 566 empty vector, in the presence or absence of Camostat (25µM). Syncytia formation was visualized 24 hours 567 post-transfection using fluorescence microscopy. (C, E) Effector 293T cells transfected with plasmids 568 encoding SARS-CoV-1 or SARS-CoV-2 S and ZipVenus1, were co-cultured with target 293T cells transfected 569 with plasmid encoding ZipVenus 2, ACE2 and TMPRSS2, TMPRRS13 or empty vector, in the presence or 570 absence of indicated protease inhibitors (Camostat 25µM, E64D 10µM, GIX 25402X3 10µM, TAPI-2 40µM, 571

Batimastat 10µM). Fluorescence generated by the reconstitution of ZIPVenus upon cell-cell fusion was 572 measured at 4 hours of co-culture. (F) 293T cells transfected with plasmids encoding GFP and SARS-CoV-573 2 S were co-cultured (1:1 ratio) with Calu-3 cells in the presence of the indicated inhibitors (Camostat 574 25µM, GIX 10µM). Syncytia were visualized 24 hours post-transfection using fluorescence microscopy. 575

Each bar shows the mean of triplicate values of 3 independent experiments with error bars showing 576 standard deviation. Significance was determined by analysis of variance (one-way ANOVA) followed by a 577

Dunnett's multiple comparisons test. P-value lower than 0.05 was used to indicate a statistically significant 578 difference (****, P <0.0001, ***, P <0.001, **, P <0.01, *, P<0.05). 579 showing standard deviation. Significance was determined by analysis of variance (one-way ANOVA) 632 followed by a Dunnett's multiple comparisons test. P-value lower than 0.05 was used to indicate a 633 statistically significant difference (****, P <0.0001, ***, P <0.001, **, P <0.01, *, P<0.05). 293T-ACE2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The trinity of COVID-19: immunity, inflammation and intervention

Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. 696 Nature

Viral membrane fusion

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 701 Clinically Proven Protease Inhibitor

Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role 703 of Proteases beyond Furin

The furin cleavage site in the SARS-CoV-2 spike protein is required for 705 transmission in ferrets

A Multibasic Cleavage Site in the Spike 707 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Functional evaluation of the P681H mutation on the proteolytic activation of 710 the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. iScience

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and 712 fusogenicity

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. 714 Nature

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for 716 drug discovery and development

Syncytia formation by SARS-CoV-2-infected cells

Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and 722 cytopathic effects

SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their 724 Requirements for Receptor Expression and Proteolytic Activation

Matrix metalloproteinases and the regulation of tissue 727 remodelling

Multifaceted role of matrix metalloproteinases (MMPs). Frontiers in Molecular 729

Distinct and early increase in circulating MMP-9 in COVID-19 patients with 731 respiratory failure. The Journal of infection

Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells 733 Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19. The Journal 734 of Infectious Diseases

Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-736 19 patients

Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome 738

Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral 739 Immune Response

Antiviral Potential of the Antimicrobial Drug Atovaquone against 741 SARS-CoV-2 and Emerging Variants of Concern

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal 743 enterocytes

TMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein. Viruses

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related 747 proteases and its metabolite GBPA exerts antiviral activity. eBioMedicine, 2021. 65

Cleavage and Activation of the Severe Acute Respiratory Syndrome 749

Coronavirus Spike Protein by Human Airway Trypsin-Like Protease

Intracellular autoactivation of TMPRSS11A, an airway epithelial transmembrane 752 serine protease

The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned 754 towards temperature and proteases of the human airways

Activation of the SARS coronavirus spike protein via 757 sequential proteolytic cleavage at two distinct sites

Potential differences in cleavage of the S protein and type-1 interferon 760 together control human coronavirus infection, propagation, and neuropathology within the 761 central nervous system

SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion 763 initiation

Cell-type-resolved quantitative proteomics map of interferon response against 765 SARS-CoV-2. iScience

TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host 767 cells. The EMBO journal

ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing

Hodgkin lymphoma cells to NKG2D-mediated killing

Enhanced potency of the metalloprotease inhibitor TAPI-2 by multivalent 771 display

Comprehensive and systemic optimization for improving the yield of 773 SARS-CoV-2 spike pseudotyped virus

Functional differences among the spike glycoproteins of multiple emerging 776 severe acute respiratory syndrome coronavirus 2 variants of concern. iScience

Rapid assessment of SARS-CoV-2&#x2013;evolved variants using virus-like 778 particles

Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike 780

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune 782 cross-reactivity with SARS-CoV

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care 784 workers, and convalescent plasma donors

SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-786 like particles

The SARS-CoV-2 variants associated with infections in India, B.1.617, show 788 enhanced spike cleavage by furin. bioRxiv

QTQTN motif upstream of the furin-cleavage site plays key role in SARS-CoV-2 790 infection and pathogenesis. bioRxiv

Identification of Common Deletions in the Spike Protein of Severe Acute Respiratory 792 Syndrome Coronavirus 2

The SARS-CoV-2 Transcriptome and the Dynamics of the S Gene Furin Cleavage 794 Site in Primary Human Airway Epithelia. mBio

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. 796 Nature

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. 798 Nature

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of 800 advanced COVID-19 pathology. EBioMedicine

SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination

SARS-CoV-2 spreads through cell-to-cell transmission

SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway 806 Epithelial Cells. Viruses

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the 808 Respiratory Tract

The protein expression profile of ACE2 in human tissues

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the 812 potential risk of different human organs vulnerable to 2019-nCoV infection

Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 815

Is Lower in Children Than Adults and Increases with Smoking and COPD

MMP-2 and MMP-9 levels in plasma are altered and associated with mortality 818 in COVID-19 patients

An immune-based biomarker signature is associated with mortality in COVID-820 19 patients

A neutrophil activation signature predicts critical illness and mortality in 822 COVID-19

Complex Immune Dysregulation in COVID-19 Patients with 824 Severe Respiratory Failure

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell 826 Compartment

Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent 828 catalytic stimulator of angiogenesis

B.1.617.2 enters and fuses lung cells with increased efficiency and evades 831 antibodies induced by infection and vaccination

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. 833 Nature

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta 835 (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet 836 Infectious Diseases

Omicron adopts a different strategy from Delta and other variants to adapt to host. 838 Signal Transduction and Targeted Therapy

Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 840 variant B.1.1.529. bioRxiv

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in 842 South Africa: a data linkage study. The Lancet

The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, 844 transmissibility, and fitness in the golden Syrian hamster model. bioRxiv

Clinical Severity and mRNA Vaccine Effectiveness for Omicron

CoV-2 Variants in the United States: A Prospective Observational Study. medRxiv

Characteristics and Outcomes of Hospitalized Patients in South Africa During the 850 COVID-19 Omicron Wave Compared With Previous Waves

Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry 852 pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein

Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis. Biomolecules

Identification of driver genes for critical forms of COVID-19 in a deeply 857 phenotyped young patient cohort

TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by 859 TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike 860

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 862 mRNA vaccination with a 16-week interval between doses

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving 865 BNT162b2 mRNA vaccination with a 16-weeks interval between doses

Contribution of single mutations to selected SARS-CoV-2 emerging variants 869 spike antigenicity

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A toolkit of protein-fragment complementation assays for studying and 873 dissecting large-scale and dynamic protein-protein interactions in living cells

Omicron mutations enhance infectivity and reduce antibody neutralization of 876 SARS-CoV-2 virus-like particles. medRxiv

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies 878 require Fc function for optimal efficacy

Major role of IgM in the neutralizing activity of convalescent plasma against 880 SARS-CoV-2